| Preparation and evaluation of spray-dried hyaluronic acid microspheres for intranasal delivery of fexofenadine hydrochloride Y Huh, HJ Cho, IS Yoon, MK Choi, JS Kim, E Oh, SJ Chung, CK Shim, ... European Journal of Pharmaceutical Sciences 40 (1), 9-15, 2010 | 93 | 2010 |
| Interspecies scaling and prediction of human clearance: comparison of small-and macro-molecule drugs Y Huh, DE Smith, M Rose Feng Xenobiotica 41 (11), 972-987, 2011 | 85 | 2011 |
| Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patients N Gupta, Y Huh, MM Hutmacher, S Ottinger, AM Hui, K Venkatakrishnan Cancer chemotherapy and pharmacology 76, 507-516, 2015 | 31 | 2015 |
| Impact of lipopolysaccharide-induced inflammation on the disposition of the aminocephalosporin cefadroxil Y Huh, RF Keep, DE Smith Antimicrobial agents and chemotherapy 57 (12), 6171-6178, 2013 | 18 | 2013 |
| Application of a hazard-based visual predictive check to evaluate parametric hazard models Y Huh, MM Hutmacher Journal of pharmacokinetics and pharmacodynamics 43 (1), 57-71, 2016 | 16 | 2016 |
| Evolution of ritlecitinib population pharmacokinetic models during clinical drug development J Wojciechowski, V S Purohit, Y Huh, C Banfield, T Nicholas Clinical Pharmacokinetics 62 (12), 1765-1779, 2023 | 7 | 2023 |
| Evaluation of the impact of ritlecitinib on organic cation transporters using sumatriptan and biomarkers as probes X Wang, V Purohit, ME Dowty, D Rodrigues, L Luo, S Mathialagan, ... The Journal of Clinical Pharmacology 63 (7), 784-797, 2023 | 6 | 2023 |
| Evaluation of QT liability for PF‐05251749 in the presence of potential circadian rhythm modification Y Huh, D Chen, S Riley, C Chang, T Nicholas CPT: Pharmacometrics & Systems Pharmacology 9 (1), 60-69, 2020 | 5 | 2020 |
| Importance of peptide transporter 2 on the cerebrospinal fluid efflux kinetics of glycylsarcosine characterized by nonlinear mixed effects modeling Y Huh, SM Hynes, DE Smith, MR Feng Pharmaceutical research 30, 1423-1434, 2013 | 5 | 2013 |
| Leveraging prior healthy participant pharmacokinetic data to evaluate the impact of renal and hepatic impairment on ritlecitinib pharmacokinetics V Purohit, Y Huh, J Wojciechowski, A Plotka, S Salts, J Antinew, ... The AAPS Journal 25 (3), 32, 2023 | 4 | 2023 |
| Virtual bioequivalence assessment of Ritlecitinib capsules with incorporation of observed clinical variability using a physiologically based pharmacokinetic model A Saadeddin, V Purohit, Y Huh, M Wong, A Maulny, ME Dowty, K Sagawa The AAPS Journal 26 (1), 17, 2024 | 3 | 2024 |
| Moving Beyond Boundaries: Utilization of Longitudinal Exposure–Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm Y Huh, J Wojciechowski, VS Purohit Clinical Pharmacokinetics 63 (3), 381-394, 2024 | 2 | 2024 |
| Utilization of rosuvastatin and endogenous biomarkers in evaluating the impact of ritlecitinib on BCRP, OATP1B1, and OAT3 transporter activity Y Huh, A Plotka, H Wei, J Kaplan, N Raha, J Towner, VS Purohit, ... Pharmaceutical Research 40 (11), 2639-2651, 2023 | 2 | 2023 |
| Cardiac risk assessment based on early Phase I data and PK-QTc analysis is concordant with the outcome of thorough QTc trials: an assessment based on eleven drug candidates P Gaitonde, Y Huh, B Darpo, G Ferber, G Heimann, J Li, K Lu, ... Journal of Pharmacokinetics and Pharmacodynamics 46, 617-626, 2019 | 2 | 2019 |
| Assessment of the Effects of Abrocitinib on the Pharmacokinetics of Probe Substrates of Cytochrome P450 1A2, 2B6 and 2C19 Enzymes and Hormonal Oral Contraceptives in Healthy … X Wang, ME Dowty, S Tripathy, VH Le, Y Huh, M Curto, JA Winton, ... European Journal of Drug Metabolism and Pharmacokinetics 49 (3), 367-381, 2024 | 1 | 2024 |
| Population pharmacokinetic modelling and simulation of tafamidis in healthy subjects and patients with transthyretin amyloidosis Y Huh, S Riley, L Harnisch, T Nicholas British Journal of Clinical Pharmacology 87 (9), 3574-3587, 2021 | 1 | 2021 |
| 15433 Assessment of cytochrome P450 3A inhibition and induction of abrocitinib: Midazolam drug-drug interaction (DDI) study and oral contraceptive DDI study X Wang, Y Huh, M Curto, G Chan, ME Dowty, M O'Gorman, S Tripathy, ... Journal of the American Academy of Dermatology 83 (6), AB151, 2020 | 1 | 2020 |
| Interspecies pharmacokinetic scaling and the prediction of human pharmacokinetics using animal and cell models MR Feng, N Zheng, X Zhang, YM Huh, J Yu Encyclopedia of Drug Metabolism and Interactions, 1-36, 2011 | 1 | 2011 |
| More Than a Gut Feeling─ A Combination of Physiologically Driven Dissolution and Pharmacokinetic Modeling as a Tool for Understanding Human Gastric Motility M Romański, M Staniszewska, J Dobosz, D Myslitska, J Paszkowska, ... Molecular Pharmaceutics 21 (8), 3824-3837, 2024 | | 2024 |
| Correction: Virtual Bioequivalence Assessment of Ritlecitinib Capsules with Incorporation of Observed Clinical Variability Using a Physiologically Based Pharmacokinetic Model A Saadeddin, V Purohit, Y Huh, M Wong, A Maulny, ME Dowty, K Sagawa The AAPS Journal 26 (2), 27-27, 2024 | | 2024 |
